Skip to content
Decision-ready map
• Start with a safe first use case (avoid high-stakes gating too early)
• Map sex-linked biology → signal shift → harm pathway
• Pilot with sex-disaggregated reporting + at least one mediator (Hb/life stage)
• Choose guardrails: mismatch rule, uncertainty display, human-in-the-loop
• Plan for scale: partnerships, evidence dossier, post-update monitoring
(1) What it is
For early-stage innovators, sex-based differences are a generalizability stress test. Hb, skin scattering, and perfusion differences can shift optical signatures and break simplistic thresholds—especially in pregnancy/anemia contexts. Validate by choosing a low-harm first use case, adding guardrails, and generating sex-disaggregated evidence early.
(2) Who it helps
Pre-startup innovators exploring device, algorithm, service, or deployment concepts before a full company/regulatory path is set.
(3) What evidence exists
Sex-dependent PPG features (Dehghanojamahalleh & Kaya 2019) and PPG best practices (Charlton et al. 2022). Population DRS shows sex-associated absorption/scattering (Jonasson et al. 2023; Hung et al. 2015). Microcirculation differences affect reliability (Samils et al. 2023). NIRS baseline oxygenated hemoglobin differs by sex (Asahara & Matsukawa 2023). WHO Hb cutoffs differ by sex/pregnancy (WHO 2024).
(4) Translation barriers
Use-case inflation (starting with diagnosis), treating sex as label without mediators, underpowered pilots, and update drift without planned change control.
(5) Equity/safety checks
Commit to sex-disaggregated reporting and transparent limitations; include pregnancy/anemia if relevant; implement mismatch rules, uncertainty displays, and human oversight; respect privacy and avoid conflating sex with gender identity.
(6) Decision questions
• What first use case avoids making one optical number a hard gate?
• What harm pathway arises from sex-linked baseline shifts?
• What minimal reference standard can be collected early and reported by sex?
• What guardrails will you implement?
• How will you revalidate after updates and monitor drift at scale?
(7) Practical next steps
1) Write a one-page sex-linked failure-mode map.
2) Choose a low-risk first deployment and define guardrails.
3) Pilot with sex-disaggregated reporting + one mediator (Hb or life stage).
4) Build an evidence dossier early (conditions, limits, uncertainty handling).
5) Plan change control and post-deployment subgroup monitoring.
(8) References
Dehghanojamahalleh S, Kaya M. Sex-Related Differences in Photoplethysmography Signals Measured From Finger and Toe. IEEE J Transl Eng Health Med. 2019;7:1900607.
https://doi.org/10.1109/JTEHM.2019.2938506
Charlton PH, Pilt K, Kyriacou PA. Establishing best practices in photoplethysmography signal acquisition and processing. Physiol Meas. 2022;43(5):050301.
https://doi.org/10.1088/1361-6579/ac6cc4
Jonasson H, Fredriksson I, Bergstrand S, et al. Absorption and reduced scattering coefficients in epidermis and dermis from a Swedish cohort study. J Biomed Opt. 2023;28(11):115001.
https://doi.org/10.1117/1.JBO.28.11.115001
Samils L, Henricson J, Strömberg T, Fredriksson I, Iredahl F. Workload and sex effects in comprehensive assessment of cutaneous microcirculation. Microvasc Res. 2023;148:104547.
https://doi.org/10.1016/j.mvr.2023.104547
Asahara R, Matsukawa K. Prefrontal oxygenation is quantified with time-resolved NIRS: effect of sex on baseline oxygenation and response during exercise. Am J Physiol Regul Integr Comp Physiol. 2023;325:R31–R44.
https://doi.org/10.1152/ajpregu.00048.2023
Morvová M Jr, Jeczko P, Šikurová L. Gender differences in the fluorescence of human skin in young healthy adults. Skin Res Technol. 2018;24(4):599–605.
https://doi.org/10.1111/srt.12471
Hung C-H, Chou T-C, Hsu C-K, Tseng S-H. Broadband absorption and reduced scattering spectra of in-vivo skin using δ-P1 approximation. Biomed Opt Express. 2015;6(2):443–456.
https://doi.org/10.1364/BOE.6.000443
Staritzbichler R, Hunold P, Estrela-Lopis I, et al. Raman spectroscopy on blood serum samples of patients with end-stage liver disease. PLoS One. 2021;16(9):e0256045.
https://doi.org/10.1371/journal.pone.0256045
WHO. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. 2024.
https://www.who.int/publications/i/item/9789240088542
NIH Office of Research on Women’s Health. Sex as a Biological Variable (SABV).
https://orwh.od.nih.gov/sex-as-biological-variable
FDA. Evaluation of Sex-Specific Data in Medical Device Clinical Studies (final guidance). March 2025.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug